Ryan Preblick - 03 Mar 2026 Form 4 Insider Report for Indivior Pharmaceuticals, Inc. (INDV)

Role
Chief Financial Officer
Signature
/s/Alice Givens, Power of Attorney
Issuer symbol
INDV
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 16:00:14 UTC
Previous filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Preblick Ryan Chief Financial Officer 10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD /s/Alice Givens, Power of Attorney 05 Mar 2026 0002014866

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INDV Common Stock Tax liability -87,597 -28% $31.98* 230,343 03 Mar 2026 Direct F1
transaction INDV Common Stock Options Exercise +86,949 +38% 317,292 03 Mar 2026 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INDV Performance Stock Units Options Exercise -113,510 -100% 0 03 Mar 2026 Common Stock 113,510 $0.000000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In 2024, 204,904 shares vested in respect of performance stock units granted to the Reporting Person on March 3, 2021. These shares were subject to a further two-year holding period. On March 3, 2026, the holding period ended and 87,597 shares were withheld to satisfy tax withholding obligations.
F2 Represents the vesting of performance stock units upon the determination that the performance conditions were met at 76.6% with respect to the performance stock units granted to the Reporting Person on March 3, 2023, of which 86,949 shares vested out of the 113,510 target amount. These shares will be released following a two-year holding period.
F3 Each performance stock unit represents a contingent right to receive one share of the Issuer's common stock.